Luke Maese
( out of 24 reviews )

Luke Maese, DO

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-662-4700
Get Directions

Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise and co-Director of the Bone Marrow Failure program within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trial development in pediatric acute lymphoblastic leukemia. He is a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

For questions regarding Dr. Maese's family cancer assessment clinic practice at the Huntsman Cancer Institute please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-9555 or go to Family History of Cancer | Huntsman Cancer Institute | University of Utah Health for more information.

For questions regarding Dr. Maese's pediatric practice and the Leukemia/Lymphoma Program at Primary Children's Medical Center, please call (801) 662-4700.

Specialties

Board Certification

American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Patient Rating

5.0 /5
( out of 24 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Dec 19, 2025
HUNTSMAN CANCER CENTER

Very courteous. Very concerned about my health. Very helpful in getting me set up for my next round of test and scans. Overall treated me with respect and care.

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Board Certification and Academic Information

Academic Departments Pediatrics -Professor (Clinical)
Academic Divisions Hematology/Oncology
Board Certification
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Education history

Fellowship Pediatric Hematology/Oncology - University of Utah Fellow
Residency Pediatrics - Children’s Hospital of Pittsburgh of UPMC Resident
Professional Medical Osteopathic Medicine - Kansas City University of Medicine and Biosciences D.O.
Undergraduate Human Biology - University of Kansas B.G.S.

Selected Publications

Journal Article

  1. Parra Del Riego A, Parker K, Thomsen WC, Ford JB, Heneghan MB, Mangum DS, McNeer JL, Maese LD, Miller CEF, Lemons R, Ghosh T (2026). Blinatumomab Utilization in Pediatric B-Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West. Pediatr Blood Cancer, 73(7), e70383.
  2. Orgel E, Maese LD, Devidas M, Militano O, Rau RE, Angiolillo A, McNeer J, Schore RJ, Borowitz MJ, Wood BL, Raetz EA, Silverman LB, Winick NJ, Larsen EC, Carroll WL, Winter SS, Dunsmore KP, Hunger SP, Loh ML (2026). Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group. Blood Adv.
  3. MacFarland SP, Goodman VE, King-Dowling S, Zelley K, Crompton BD, Schultz KAP, Maese LD, Maxwell KN, Khincha PP, Schwartz LA (2026). Liquid Biopsy for Cancer Screening in Li-Fraumeni Syndrome: Interest in Clinical Trial and Reported Barriers to Standard of Care Screening. Cancer Prev Res (Phila).
  4. Spiegel SR, Orr C, Edgar NU, Cahill SR, Le AN, Good M, Lyman J, Feola S, Mehrhoff C, Naumer A, Vagher J, Anez I, Frucht N, Maese LD, Garber JE, Maoz A, Katona BW, MacFarland SP, Maxwell KN (2026). Colorectal Neoplasia Rates in Li-Fraumeni Syndrome. Am J Gastroenterol.
  5. Kang W, Lazo de la Vega L, Comeau H, Agastra E, Maese LD, Kim A, Sukharevsky E, Ceca E, Corson L, White J, Weiser DA, Applebaum MA, Colace SI, Chen M, Johnson JA, Volchenboum S, Pinto NR, Church AJ, Janeway KA (2026). Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies. Commun Med (Lond), 6(1), 88.
  6. Kamihara J, Fisher L, Schienda J, Vanderwall R, Snir M, Snir G, Simmons E, Khalaj A, Goler E, Hamilton KV, Porter CC, Pencheva B, Schiffman JD, Maese LD, Kohlmann W, Henderson TO, Garber JE, Diller LR, Desai AV, Savage S, Klosky JL, Rana HQ, Mack JW (2026). Development and pilot testing of AYA-RISE, a risk information and screening education intervention for adolescents and young adults with cancer risk syndromes. Fam Cancer, 25(1), 11.
  7. Mathis CL, Meeks HD, Watt KM, Maese LD, Constance JE (2025). Acetaminophen and Acetaminophen-Opioid Combination Prescribing Trends Among Hospitalized Children, Adolescents, and Young Adults with Cancer. Pharmacol Res Rep, 4.
  8. Sharma R (2025). Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition. Blood Neoplasia, 2(4).
  9. Aldoss I, Ali A, Cassaday RD, Curran EK, Luskin MR, Maese LD, Orgel E, Douer D (2025). Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations. Am J Hematol.
  10. Sleiman MM Jr, Statman MR, Yockel MR, Wu YP, Hamilton JG, Kohlmann WK, Vagher J, Feola S, Maese LD, Chen J, Appel B, Mehrhoff CJ, Peshkin BN, Kadan-Lottick NS, Kupfer GM, Tercyak KP (2025). Parental perspectives on the use of tumor molecular profiling and germline genetic testing during their children's cancer treatment. Fam Cancer, 24(3), 63.
  11. Fernandes CJ, Du YK, Naumer A, Kagami LA, Le A, Good M, Duvall M, Powers J, Zelley K, Maese LD, MacFarland S, Kohlmann W, Maxwell KN, Katona BW (2025). Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome. Pancreas, 54(7), e618-e623.
  12. Sharma R, Zhang C, Shah R, Frigault MM, Johnson AJ, Mangum DS, Maese LD, Lacayo NJ, Narendran A (2025). Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition. Blood Neoplasia, 2(4), 100148.
  13. Vagher J, Zakas A, Donovan L, Shoger K, Naumer A, Bly J, Smith-Simmer K, Maese L, Schiffman J, Kohlmann W, Garzon R, Churpek JE, Osman AEG (2025). Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome. JCO Precis Oncol, 9, e2400860.
  14. Mathis CL, Meeks HD, Watt KM, Maese LD, Constance JE (2025). Acetaminophen and Acetaminophen-Opioid Combination Prescribing Trends Among Hospitalized Children, Adolescents, and Young Adults with Cancer.
  15. Achatz MI, Villani A, Bertuch AA, Bougeard G, Chang VY, Doria AS, Gallinger B, Godley LA, Greer MC, Kamihara J, Khincha PP, Kohlmann WK, Kratz CP, MacFarland SP, Maese LD, Maxwell KN, Mitchell SG, Nakano Y, Pfister SM, Wasserman JD, Woodward ER, Garber JE, Malkin D (2025). Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res.
  16. Nakano Y, Kuiper RP, Nichols KE, Porter CC, Lesmana H, Meade J, Kratz CP, Godley LA, Maese LD, Achatz MI, Khincha PP, Savage SA, Doria AS, Greer MC, Chang VY, Wang LL, Plon SE, Walsh MF (2024). Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders. Clin Cancer Res, 30(22), 5009-5020.
  17. Maese LD, Loh ML, Choi MR, Agarwal S, Aoki E, Liang Y, Lin T, Girgis S, Chen C, Roller SG, Chandrasekaran V, Iannone R, Silverman LB, Raetz EA, Rau RE (2024). Recombinant Erwinia Asparaginase (JZP458) in ALL/LBL: Complete Follow-Up of the Children's Oncology Group AALL1931 Study. Blood Adv.
  18. Maese LD, Wlodarski MW, Kim SY, Bertuch AA, Bougeard G, Chang VY, Godley LA, Khincha PP, Kuiper RP, Lesmana H, McGee RB, McReynolds LJ, Meade J, Plon SE, Savage SA, Scollon SR, Scott HS, Walsh MF, Nichols KE, Porter CC (2024). Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy. Clin Cancer Res.
  19. Beigh M, Vagher J, Codden R, Maese LD, Cook S, Gammon A (2024). Newborn Screening for Li-Fraumeni Syndrome: Patient Perspectives. Res Sq.
  20. Fair D, Maese L, Chi YY, Li M, Hawkins DS, Venkatramani R, Rudzinski E, Parham D, Teot L, Malkin D, Plon SE, Li H, Sabo A, Lupo PJ, Schiffman JD (2023). TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report. Pediatr Blood Cancer, e30413.
  21. Fan EM, Vagher J, Meznarich JA, Ubico EM, Goteti S, Peterson D, Rayes A, Maese LD (2023). Severe congenital neutropenia, SRP54 pathogenicity, and a framework for surveillance. Am J Med Genet A, 191(5), 1434-1441.
  22. Foley M, Sharma A, Garfield K, Maese L, Buchmann L, Boyle J, Kohlmann W, Jeter J, Greenberg S (2022). A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant. Fam Cancer, 22(2), 217-224.
  23. Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA (2024). Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol, 7, e2200334.
  24. Maese LD, Loh ML, Choi MR, Lin T, Aoki E, Zanette M, Agarwal S, Iannone R, Silverman JA, Silverman LB, Raetz EA, Rau RE (2022). Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. . Blood, 141(7), 704-712.
  25. Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest SJ (2022). Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol, 6, e2200390.
  26. MacFarland SP, Maese L, Rednam SP, Kamihara J, Perrino MR, Nichols KE, Brodeur GM, Schiffman JD, Plon SE, Diller LR, Malkin D, Porter CC, Villani A (2022). Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer Prev Res (Phila), 15(10), OF1-OF7.
  27. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA (2022). Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med, 28(8), 1581-1589.
  28. Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E (2022). Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG). Neuro Oncol, 24(10), 1776-1789.
  29. Maxwell KN (2022). Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol, 81(3), 243-250.
  30. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clin Neurol Neurosurg, 212, 107064.
  31. Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J (2021). Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol, 5.
  32. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC (2021). Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol.
  33. Iglesias Cardenas F, Agarwal AM, Vagher J, Maese L, Fluchel M, Afify Z (2020). Two Clonally Distinct B-Cell Lymphomas Reveal the Diagnosis of XLP1 in a Male Child and His Asymptomatic Male Relatives: Case Report and Review of the Literature. J Pediatr Hematol Oncol, 43(8), e1210-e1213.
  34. Maese L, Rizzari C, Coleman R, Power A, van der Sluis I, Rau RE (2021). Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? Pediatr Blood Cancer, 68(10), e29169.
  35. Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman JD (2022). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol, 7(10), 1521-1528.
  36. Bender C, Maese L, Carter-Febres M, Verma A (2021). Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood Lymphat Cancer, 11, 25-40.
  37. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance JE (2020). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. J Adolesc Young Adult Oncol, 10(2), 175-184.
  38. Lozano-Chinga M, Draper L, George TI, Agarwal AM, Dansie DM, Maese L (2020). Bone marrow necrosis in pediatric malignancies: 10-Year retrospective review and review of literature. Pediatr Blood Cancer, 68(3), e28806.
  39. Olson J, Mehra S, Hersh AL, Thorell EA, Stoddard GJ, Maese L, Barnette PE, Lemons RS, Pavia AT, Knackstedt ED (2019). Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. J Pediatric Infect Dis Soc, 10(1), 27-33.
  40. Kim J, Light N, Subasri V, Young EL, Wegman-Ostrosky T, Barkauskas DA, Hall D, Lupo PJ, Patidar R, Maese LD, Jones K, Wang M, Tavtigian SV, Wu D, Shlien A, Telfer F, Goldenberg A, Skapek SX, Wei JS, Wen X, Catchpoole D, Hawkins DS, Schiffman JD, Khan J, Malkin D, Stewart DR (2021). Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precis Oncol, 5.
  41. Thomsen W (2021). Early presentation of homozygous mismatch repair deficient glioblastoma in teen with lynch syndrome: Implications for treatment and surveillance. JCO Precis Oncol, 5, 670-675.
  42. Kim J (2021). Pathogenic germline variants in cancer susceptibility genes in children and young adults with rhabdomyosarcoma. JCO Precis Oncol, 5, 75-87.
  43. Kerrigan K (2021). Lung cancer in li-fraumeni syndrome. JCO Precis Oncol, 5, 552-556.
  44. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz E (2020). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, Online ahead of print, 178-186.
  45. Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, Lloyd S, Kokeny KE, Hitchcock YJ, Poppe MM, Gaffney DK, Tao R (2020). Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study. Cancer Med, 9(21), 7954-7963.
  46. Donovan LN (2020). Germ cell mosaicism: A rare cause of Li-Fraumeni recurrence among siblings. JCO Precis Oncol, 4, 662-664.
  47. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba N (2020). Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(1), 81-112.
  48. Maese L, Raetz EA (2019). Can Ph-like ALL be effectively targeted? Best Pract Res Clin Haematol, 32(4), 101096.
  49. Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols KE (2019). Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia? J Clin Oncol, 37(24), 2098-2104.
  50. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman JD (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatr Blood Cancer, 66(5), e27629.
  51. Maese L, Li KD, Xu X, Afify Z, Paxton CN, Putnam A (2017). Acute Leukemia and Concurrent Mediastinal Germ Cell Tumor: Case Report and Literature Review. Fetal Pediatr Pathol, 36(2), 168-176.

Review

  1. Vagher J, Mehrhoff CJ, Florou V, Maese LD (2024). Genetic Predisposition to Sarcoma: What Should Clinicians Know? [Review]. Curr Treat Options Oncol, 25(6), 769-783.
  2. Maese LD, Pulsipher MA (2023). Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL. [Review]. J Clin Oncol, 41(25), 4087-4092.
  3. Maese L (2022). Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. [Review]. Front Pediatr, 10.
  4. Maese L, Rau RE (2022). Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. [Review]. Front Pediatr, 10, 902117.
  5. Vagher J, Dietz MS, Schiffman JD, Kohlmann W, Maese L (2022). Germline predisposition to soft tissue sarcoma. [Review]. J Cancer Metastasis Treat, 8.

Book Chapter

  1. Hogan LE (2022). Treatment of Pediatric B- and T-Cell Acute Lymphoblastic Leukemia. In Hogan L.E. (Ed.), Clinical Management of Acute Lymphoblastic Leukemia from Bench to Bedside (pp. 75-104).
  2. Vagher J (2021). Inherited risk for childhood leukemia. In Vagher J. (Ed.), Hereditary Basis of Childhood Cancer (pp. 315-360).
  3. Greenberg SE (2020). Von Hippel-Lindau syndrome. In Greenberg S.E. (Ed.), JCO Precis Oncol (pp. 1005-1020).

Letter

  1. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. [Letter to the editor]. Br J Haematol, 198(6), e78-e81.

News & Podcasts

Huntsman Cancer Institute News

Schedule Online